Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Adalimumab Induction for Treatment of Steroid Dependent Immune Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical Trial

NCT06037811 is registered in ClinicalTrials.gov with Tom Appleton as lead sponsor.

NCT NCT06037811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06037811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Adalimumab Induction for Treatment of Steroid Dependent Immune Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical Trial
Lead sponsor
Tom Appleton
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2024
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune-related adverse event, inflammatory arthritis